Reports and Updates
NEW COVID-19 Infections in Manitoba: Race, Ethnicity, and Indigeneity
Data from around the world has shown COVID-19 infections are not evenly distributed by population groups. Data has shown that Black, Indigenous and People of Colour (BIPOC) are overrepresented in COVID-19 infections. This report includes data from May 1, 2020 to Dec. 31, 2020, and provides data and context on how COVID-19 has affected BIPOC communities in Manitoba.
- COVID-19 Infections in Manitoba: Race, Ethnicity, and Indigeneity | External Report
- COVID-19 Infections in Manitoba: Race, Ethnicity, and Indigeneity | Public Brief
- COVID-19 Infections in Manitoba: Race, Ethnicity, and Indigeneity | Analysis - Wave Three
Epidemiology of COVID-19 in Manitoba: March 12 to May 1, 2020
The purpose of this report is to provide a descriptive epidemiological summary of COVID-19 infections in Manitoba between March 12 and May 1. Manitoba’s experience in this period appears to be unique nationally: compared to many jurisdictions, Manitoba has had fewer cases, a tighter rise and fall in infection counts, and fewer critical outbreaks in places like long-term care facilities. This may be in direct relation to the public health measures imposed. It is important to reflect on the dynamics of these seven weeks, to better prepare Manitoba for the likelihood of a resurgence of COVID-19 cases.
The report is set up in three sections to provide quick access to specific information relating to three key parts of the COVID-19 "story" in Manitoba: cases, testing, and contacts.
- Epidemiology of COVID-19 in Manitoba: March 12 to May 1, 2020 - Report
- Epidemiology of COVID-19 in Manitoba: March 12 to May 1, 2020 - Infographic
Provincial Respiratory Surveillance Report (Seasonal Influenza Report) NEW
Epidemiology and Surveillance (E&S) unit monitors COVID-19 and influenza activity throughout the year. Starting from the Week 45 (November 6–12) in 2022–2023, the E&S unit started to post the new respiratory surveillance report that combines surveillance indicators and intelligence around COVID-19, influenza and other respiratory pathogens. In this weekly report, E&S provides regular updates about the current activity of COVID-19 and influenza within the respiratory context to better monitor trends and guide prevention and control recommendations throughout the respiratory season. Updates around corresponding immunization coverage are also included.
Sexually Transmitted and Blood-Borne Infection (STBBI) Surveillance Report NEW
The Epidemiology and Surveillance Unit of Manitoba Health conducts routine surveillance of reportable sexually transmitted and blood-borne infections (STBBIs) as outlined within the The Public Health Act and Reporting of Diseases and Conditions Regulations. Under this legislation, laboratories and health care professionals report notifiable STBBIs to the Manitoba Health Surveillance Unit (MHSU) ; after which health care professionals and regional public health teams complete follow-up of these cases as defined by provincial disease management protocols. The outcomes of these investigations are documented in the provincial Public Health Information Management System (PHIMS).
The STBBI Surveillance Report presents summary statistics for reported cases of chlamydia, gonorrhea, hepatitis B, hepatitis C, syphilis (infectious, non-infectious, and congenital), and HIV in Manitoba. These data are updated on a quarterly basis with a three-month delay for validation purposes.
Take Home Naloxone Kit Use Report NEW
The objective of this report is to provide program evaluation information on how the take home naloxone program operates in the community by analyzing the data provided to MB Health through the Overdose Response Form (MHSU-6836). This form is filled out in an anonymous and confidential manner, when a participant reports using a take home naloxone kit in a suspected opioid toxicity event. This form is an integral part of the Provincial substance use and harms surveillance system, and provides an insight into the experience of using take home naloxone kits during suspected opioid toxicity events that occur in community settings. Data are analyzed by age, setting, month, substance type, naloxone usage, and other actions taken to reverse the effect of the overdose event.
This report provides epidemiological updates up to November 5, 2022 on the intensity and severity of COVID-19 in Manitoba. Surveillance and administrative data include laboratory, public health case and contact tracing investigations, hospitalization and mortality data. Data are presented at the provincial and regional level; and include a focussed review on the disproportional impact of COVID-19 on various populations in the province. Routine reporting of seasonal influenza activity in the 2020–2021 season was also included in this weekly report.
The Epidemiology and Surveillance Unit of Manitoba Health (Health) conducts routine surveillance of reportable diseases and conditions under the authority of the Public Health Act and Reporting of Diseases and Conditions Regulations. Under the legislation, laboratories and health professionals make reports respecting a reportable disease to the Health Epidemiology and Surveillance Unit.
Following the provincial protocols, health care professionals, regional public health offices and federal agencies operating in Manitoba are required to return completed investigation forms for cases and contacts (protocol-specific), also to Health’s Epidemiology and Surveillance Unit. epiSUMMARY presents monthly summary statistics of cases reported in Manitoba with a 6-month delay for validation purposes.
Manitoba provides data and analyses towards the Canadian Chronic Disease Surveillance System funded by the Public Health Agency of Canada. Through this initiative, Epidemiology and Surveillance uses administrative data to better understand the burden of non-communicable diseases within the province. If a report is not listed for a topic you are interested in, please do not hesitate to contact the team for assistance.
Annual Reports
All reports which are released on an annual basis
Surveillance data is used to identify and monitor the arrival of influenza, its geographic spread, intensity of activity, characteristics of those infected, as well as severity and changing trends in order to guide prevention and control recommendations.
This report is produced annually, at the end of each influenza season, and presents an overview of the influenza season in question. The influenza season generally runs from October to May of each year.
Annual Report of Immunization Surveillance
Immunization is one of the most effective and cost-efficient health interventions of modern times. Manitoba Health (Health) protects children and adults in Manitoba from infection of many diseases by recommending and providing routine immunizations. The provincial immunization registry from 1988 plays a key role in ensuring that residents in Manitoba receive all recommended immunizations. The aim of the Annual Report is to provide an overall picture of immunizations in the province. This information is used to inform priority setting, policy development, program planning and evaluation.
Manitoba Annual Summary of Communicable Diseases
This report utilizes surveillance data to provide an annual summary of laboratory-confirmed, communicable diseases, in Manitoba. It focuses specifically on infectious diseases listed as “reportable” under The Public Health Act with the exception of Influenza, tuberculosis, and the sexually transmitted and blood-borne infections.
Statistical Update on HIV/AIDS
This report is intended to provide HIV and AIDS surveillance information in Manitoba for new cases reported to the Public Health Surveillance Unit within Manitoba Health from 1985 up to the date of the report. The HIV data presented here includes an examination by: age and sex distribution, geographic region, ethnicity, and risk exposure category (primary mode of transmission).
Other Reports
All reports that have been released by the Epidemiology and Surveillance Unit that do not follow a repeating schedule.
Public Health 4th Floor - 300 Carlton St. |
